Form 4: Passage Bio Director, Maxine Gowen, Granted Stock Options

Maxine Gowen, a director at Passage Bio, Inc., was granted stock options to purchase 47,693 shares of common stock on May 21, 2024.

Summary

• On May 21, 2024, Maxine Gowen, a director of Passage Bio, Inc. [PASG], was granted stock options.
• The stock options allow Gowen to purchase 47,693 shares of Passage Bio's common stock at an exercise price of $1.28 per share.
• The options vest on the earlier of the one-year anniversary of the grant date or the date of the issuer's 2025 Annual Meeting of its stockholders, contingent upon Gowen's continuous service to the issuer.
• The options expire on May 21, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard grant of stock options to a director, which is generally viewed as a positive incentive but not a major event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize directors and align their interests with those of shareholders. This is a standard form 4 filing.

Stakeholder Impact

• The stock option grant could potentially benefit shareholders by aligning the director's interests with the company's long-term success.

Key Dates